We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock

Delisted

SEEL was delisted on the 15th of October, 2024.

18 hedge funds and large institutions have $129K invested in Seelos Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

38% less funds holding

Funds holding: 2918 (-11)

92% less capital invested

Capital invested by funds: $1.55M → $129K (-$1.42M)

92% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 12

Holders
18
Holders Change
-11
Holders Change %
-37.93%
% of All Funds
0.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
5
Reduced
4
Closed
12
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
26
Vanguard Group
Pennsylvania
-$166K -2,194 Closed
SFWC
27
Strategic Family Wealth Counselors
New Jersey
-$17.7K -234 Closed
Jane Street
28
Jane Street
New York
-$13.6K -180 Closed
XT
29
XTX Topco
Cayman Islands
-$9.5K -126 Closed
Two Sigma Investments
30
Two Sigma Investments
New York
-$7.73K -102 Closed
State Street
31
State Street
Massachusetts
-$7.65K -101 Closed
CFS
32
CRA Financial Services
New Jersey
-$7.03K -93 Closed
Wealth Enhancement Advisory Services
33
Wealth Enhancement Advisory Services
Minnesota
-$5.92K -78 Closed
Osaic Holdings
34
Osaic Holdings
Arizona
-$4.76K -64 Closed
First Manhattan
35
First Manhattan
New York
-$219 -3 Closed
APC
36
Aspire Private Capital
North Carolina
-$30

SEEL Hedge Fund Activity: Q2 2024 in Review

18 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2024, worth a combined $129K — down 92% from $1.55M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of SEEL and 1 opened new positions — a net loss of 11 holders — while 4 trimmed existing stakes and 5 added.

The largest buyer was AdvisorShares Investments, adding an estimated $67.4K. The largest seller was Gendell Jeffrey L, exiting entirely with an estimated $254K sold.

  • 18 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2024, down from 29 in Q1 2024.
  • Funds reported $129K of Seelos Therapeutics, Inc. Common Stock stock for Q2 2024, down 92% quarter-over-quarter.
  • 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2024 and 12 closed out, a net change of -11 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2024 was AdvisorShares Investments, an estimated $67.4K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2024 was Gendell Jeffrey L, an estimated $254K sold.

Based on aggregated 13F filings for Q2 2024.